Diabetes
| Type 2 diabetes
Diabetes
Type 2 diabetes
Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial
book_2
Source:
ADA 2021 - Poster session
calendar_today
Published on Medfyle:
July 2021
headphones
5
min
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- This post hoc analysis of the SUSTAIN-10 trial examined clinical outcomes with a GLP-1RA (semaglutide 1.0 mg or liraglutide 1.2 mg) in people with or without background SGLT2i.
- Addition of a GLP-1RA to an SGLT2i was associated with further reductions from baseline in HbA1c, body weight, and systolic blood pressure.
- There were no unexpected safety concerns in subjects receiving both a GLP-1RA and an SGLT2i.
Presenting Author
Read more
arrow_downward
Hide
arrow_upward
Matthew Capehorn
Rotherham, United Kingdom
Disclosure: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., McDonalds, Novo Nordisk, Consultant; Self; Lighterlife, Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk, Speaker's Bureau; Self; Novo Nordisk.
